Chronic Hepatitis

Top Story

Researchers find SVR from Incivek-based regimens improved liver fibrosis scores

September 4, 2015

In a retrospective analysis, researchers found that patients with hepatitis C virus infection who achieved sustained virologic response after treatment with an Incivek-based regimen showed improvement in serum markers for liver fibrosis, according to study data.

Data of 1,208 patients with HCV was collected and evaluated from the PROVE3 phase 2 clinical study and the ADVANCE and REALIZE phase 3 clinical studies that were investigating Incivek (telaprevir, Vertex Pharmaceuticals Inc.). For the analysis, all patients were divided according to severity of fibrosis measured through their baseline Metavir score, and whether or not they reached SVR after treatment. The researchers measured the patients’ scores from four biomarker tests: FibroTest, aspartate aminotransferase (AST) to Platelet Ratio Index (APRI), Fibrosis-4 (FIB-4) and Forns' Score, before and after HCV treatment.

World Hepatitis Summit aims to raise awareness of viral hepatitis

September 3, 2015
Hundreds of key leaders, policymakers and patient groups are currently attending the first-ever World Hepatitis Summit in Glasgow, Scotland, in an attempt to raise more…

Daktari collaborates with Merck for rapid HCV screening test

September 1, 2015
Daktari Diagnostics announced a new collaboration with Merck over the development of its rapid hepatitis C virus infection screening test, according to a press release…
In the Journals

HBV prevalence in rural Chinese men declines to 'intermediate endemic'

August 31, 2015
Updated baseline data suggest the prevalence of hepatitis B virus infection in men in rural China changed from highly endemic in 2006 to intermediate endemic in 2012…
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
Meeting News Coverage Video
thumbnail for video 3899432251001

New HCV treatments could reduce mortality, but increase costs by billions

November 19, 2014
BOSTON – In this video exclusive from The Liver Meeting, David B. Rein, PhD, MPA, of the National Opinion…
More »
In the Journals

Researchers find SVR from Incivek-based regimens improved liver fibrosis scores

September 4, 2015
In a retrospective analysis, researchers found that patients with hepatitis C virus infection who achieved sustained virologic response after…

World Hepatitis Summit aims to raise awareness of viral hepatitis

September 3, 2015
Hundreds of key leaders, policymakers and patient groups are currently attending the first-ever World Hepatitis Summit in Glasgow, Scotland, in an…

Daktari collaborates with Merck for rapid HCV screening test

September 1, 2015
Daktari Diagnostics announced a new collaboration with Merck over the development of its rapid hepatitis C virus infection screening test, according…
In the Journals

HBV prevalence in rural Chinese men declines to 'intermediate endemic'

August 31, 2015
Updated baseline data suggest the prevalence of hepatitis B virus infection in men in rural China changed from highly endemic in 2006 to intermediate…
In the Journals

Low vitamin D levels prevalent in untreated patients with HBV

August 31, 2015
In a new study, researchers found that untreated patients with chronic hepatitis B virus infection had significantly low levels of vitamin…

Ascletis launches phase 2 trial of interferon-free regimen for HCV

August 31, 2015
Ascletis Pharmaceuticals Co., Ltd. announced the launch of a phase 2 clinical trial in Taiwan to investigate the efficacy of its interferon-free…
In the Journals

Responses similar to double- vs. single-dose HBV revaccination in HIV patients

August 31, 2015
Researchers found no difference in seroprotection rates between a double-dose hepatitis B virus vaccine regimen and a standard single-dose regimen in…
One in four patients with HCV denied initial request for treatment In the Journals

One in four patients with HCV denied initial request for treatment

August 28, 2015
A new study published in PLoS ONE showed that one in four patients with hepatitis C virus infection who apply for treatment of the infection is…
In the Journals

Cytokines influence impaired cognitive function in children with HCV

August 27, 2015
Researchers in Egypt found a significant correlation between various endogenous cytokines and cognitive impairment among a cohort of Egyptian…

Health Canada approves Daklinza for HCV

August 21, 2015
Health Canada announced it has approved Daklinza for the treatment of chronic hepatitis C virus infection, according to a press release.Daklinza…
More Headlines »
morganatic-roan morganatic-roan